What is Bronchogen?
Bronchogen is a synthetic tetrapeptide in the tissue-specific bioregulator family. Its respiratory focus comes from the bronchial epithelium: the layer of cells that lines the airways and helps maintain their protective mucus barrier.[7]
Several primary papers identify the sequence as Ala-Asp-Glu-Leu (ADEL), while an endonuclease paper prints Ala-Glu-Asp-Leu (AEDL). The order matters because exchanging two amino acids changes the molecule; the Bronchogen name alone does not resolve this discrepancy.[7][18]
Bronchogen is distinct from Chonluten and from larger bronchial-tissue extracts. A purified short peptide, an extract and a capsule or drop formulation need their own identity and composition checks.[20]
What Bronchogen is investigated for
Bronchogen evidence is grouped by practical use case and oral and intraperitoneal route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Airway-cell maintenance
Oral
Airway-cell maintenance
Oral
Airway mucus-barrier function
Oral
Airway mucus-barrier function
Oral
Changes in mucus-related gene activity are a laboratory signal, not proof of improved mucus clearance or breathing in patients.[7]
Evidence snapshot
Overall confidence
Airway-cell biology provides a respiratory rationale. Clinical confidence remains low, with uncertain symptom benefits and differences between named preparations.[7][18][5]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human evidence for added respiratory benefit remains limited.[5][6]
Animal / preclinical
Preclinical findings concern airway-cell maintenance, obstructive lung changes and peptide–DNA interactions.[1][2][3][4]
Mechanism support
ADEL may influence genes involved in airway-cell development and mucus production, including NKX2-1 and mucins. These signals help maintain airway-cell identity and the protective surface barrier.[7]
Forms & administration
Bronchogen has oral capsules and lingual drops, with amounts determined by product strength and delivery volume. Other injectable preparations remain experimental and animal-only, separate from the oral products.[20][21][24]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
The small adjunctive human reports cannot establish common side-effect rates. The ADEL/AEDL naming discrepancy and separate capsule/drop formulations also complicate product comparison.[5][6][18]
Regulatory status
United States
Bronchogen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[22]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved Bronchogen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[22] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedBronchogen is not an FDA-approved drug name. Availability of a supplement or research preparation does not establish approval for a medical use.[22]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[22]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
ADEL may influence genes involved in airway-cell development and mucus production, including NKX2-1 and mucins. These signals help maintain airway-cell identity and the protective surface barrier.[7]
Possible interactions with DNA may help explain its effects on cell maintenance and repair. The mechanism remains experimental.[3][1]
Research gaps & open questions
What the current literature has not yet settled about Bronchogen:
The ADEL/AEDL sequence discrepancy needs resolution using a characterized reference material, so that cell findings and commercial products can be matched to the same molecule.[7][18]
Independent controlled trials should measure breathlessness, lung function and exacerbations alongside usual care. The small regional reports cannot establish how much benefit Bronchogen adds.[5][6]
Human absorption studies need to establish how much peptide reaches the bloodstream after capsules or drops, and whether either preparation reaches airway tissue at an active concentration.[14][20]
Common questions
Is Bronchogen the same as Chonluten?
No. They are separate bioregulator products with different peptide identities; results for one cannot establish the effects of the other.[20]
History & discovery
Bronchogen developed within the short-peptide bioregulator program, where investigators examined whether small sequences could alter tissue-cell activity. Airway-cell and rat experiments provide most of its molecular evidence.[4][7]
A five-patient COPD group received Bronchogen alongside standard care. This supplied an oral study schedule, but the small adjunctive design could not isolate a treatment effect.[5]
Human bronchial-cell experiments examined gene activity and protein production; rat work examined damaged airway epithelium. These studies shaped the proposed respiratory mechanism without establishing a clinical treatment.[7][1]
25 citations
Bronchogen research focuses on airway-cell maintenance, mucus-barrier signaling and respiratory symptoms. Clinical evidence remains preliminary, and sequence differences complicate comparisons between preparations.[7][18][5][6][24]
